0001757097--12-312021Q3false6-K2021-09-30Centogene N.V.00017570972021-01-012021-09-300001757097ifrs-full:BottomOfRangeMembercntg:CentogeneN.v.CentogeneGmbhAndItsSubsidiariesMember2021-09-300001757097srt:NorthAmericaMembercntg:PharmaceuticalSegmentMember2021-07-012021-09-300001757097srt:NorthAmericaMembercntg:DiagnosticsSegmentMember2021-07-012021-09-300001757097srt:NorthAmericaMembercntg:Covid19Member2021-07-012021-09-300001757097srt:LatinAmericaMembercntg:PharmaceuticalSegmentMember2021-07-012021-09-300001757097srt:LatinAmericaMembercntg:DiagnosticsSegmentMember2021-07-012021-09-300001757097srt:EuropeMembercntg:PharmaceuticalSegmentMember2021-07-012021-09-300001757097srt:EuropeMembercntg:DiagnosticsSegmentMember2021-07-012021-09-300001757097srt:EuropeMembercntg:Covid19Member2021-07-012021-09-300001757097srt:AsiaPacificMembercntg:DiagnosticsSegmentMember2021-07-012021-09-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMembercntg:PharmaceuticalSegmentMember2021-07-012021-09-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMembercntg:DiagnosticsSegmentMember2021-07-012021-09-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMembercntg:Covid19Member2021-07-012021-09-300001757097ifrs-full:PerformanceObligationsSatisfiedAtPointInTimeMembercntg:PharmaceuticalSegmentMember2021-07-012021-09-300001757097ifrs-full:PerformanceObligationsSatisfiedAtPointInTimeMembercntg:Covid19Member2021-07-012021-09-300001757097country:NLcntg:DiagnosticsSegmentMember2021-07-012021-09-300001757097country:NLcntg:Covid19Member2021-07-012021-09-300001757097country:DEcntg:DiagnosticsSegmentMember2021-07-012021-09-300001757097country:DEcntg:Covid19Member2021-07-012021-09-300001757097cntg:IfrsMiddleEastMembercntg:PharmaceuticalSegmentMember2021-07-012021-09-300001757097cntg:IfrsMiddleEastMembercntg:DiagnosticsSegmentMember2021-07-012021-09-300001757097srt:NorthAmericaMember2021-07-012021-09-300001757097srt:LatinAmericaMember2021-07-012021-09-300001757097srt:EuropeMember2021-07-012021-09-300001757097srt:AsiaPacificMember2021-07-012021-09-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMember2021-07-012021-09-300001757097ifrs-full:PerformanceObligationsSatisfiedAtPointInTimeMember2021-07-012021-09-300001757097country:NL2021-07-012021-09-300001757097country:DE2021-07-012021-09-300001757097cntg:PharmaceuticalSegmentMember2021-07-012021-09-300001757097cntg:IfrsMiddleEastMember2021-07-012021-09-300001757097cntg:DiagnosticsSegmentMember2021-07-012021-09-300001757097srt:NorthAmericaMembercntg:PharmaceuticalSegmentMember2021-01-012021-09-300001757097srt:NorthAmericaMembercntg:DiagnosticsSegmentMember2021-01-012021-09-300001757097srt:NorthAmericaMembercntg:Covid19Member2021-01-012021-09-300001757097srt:LatinAmericaMembercntg:PharmaceuticalSegmentMember2021-01-012021-09-300001757097srt:LatinAmericaMembercntg:DiagnosticsSegmentMember2021-01-012021-09-300001757097srt:EuropeMembercntg:PharmaceuticalSegmentMember2021-01-012021-09-300001757097srt:EuropeMembercntg:DiagnosticsSegmentMember2021-01-012021-09-300001757097srt:EuropeMembercntg:Covid19Member2021-01-012021-09-300001757097srt:AsiaPacificMembercntg:DiagnosticsSegmentMember2021-01-012021-09-300001757097srt:AsiaPacificMembercntg:Covid19Member2021-01-012021-09-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMembercntg:PharmaceuticalSegmentMember2021-01-012021-09-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMembercntg:DiagnosticsSegmentMember2021-01-012021-09-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMembercntg:Covid19Member2021-01-012021-09-300001757097ifrs-full:PerformanceObligationsSatisfiedAtPointInTimeMembercntg:PharmaceuticalSegmentMember2021-01-012021-09-300001757097ifrs-full:PerformanceObligationsSatisfiedAtPointInTimeMembercntg:Covid19Member2021-01-012021-09-300001757097country:NLcntg:DiagnosticsSegmentMember2021-01-012021-09-300001757097country:NLcntg:Covid19Member2021-01-012021-09-300001757097country:DEcntg:DiagnosticsSegmentMember2021-01-012021-09-300001757097country:DEcntg:Covid19Member2021-01-012021-09-300001757097cntg:IfrsMiddleEastMembercntg:PharmaceuticalSegmentMember2021-01-012021-09-300001757097cntg:IfrsMiddleEastMembercntg:DiagnosticsSegmentMember2021-01-012021-09-300001757097srt:NorthAmericaMember2021-01-012021-09-300001757097srt:LatinAmericaMember2021-01-012021-09-300001757097srt:EuropeMember2021-01-012021-09-300001757097srt:AsiaPacificMember2021-01-012021-09-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMember2021-01-012021-09-300001757097ifrs-full:PerformanceObligationsSatisfiedAtPointInTimeMember2021-01-012021-09-300001757097country:NL2021-01-012021-09-300001757097country:DE2021-01-012021-09-300001757097cntg:PharmaceuticalSegmentMember2021-01-012021-09-300001757097cntg:IfrsMiddleEastMember2021-01-012021-09-300001757097cntg:DiagnosticsSegmentMember2021-01-012021-09-300001757097srt:NorthAmericaMembercntg:PharmaceuticalSegmentMember2020-07-012020-09-300001757097srt:NorthAmericaMembercntg:DiagnosticsSegmentMember2020-07-012020-09-300001757097srt:NorthAmericaMembercntg:Covid19Member2020-07-012020-09-300001757097srt:LatinAmericaMembercntg:DiagnosticsSegmentMember2020-07-012020-09-300001757097srt:LatinAmericaMembercntg:Covid19Member2020-07-012020-09-300001757097srt:EuropeMembercntg:PharmaceuticalSegmentMember2020-07-012020-09-300001757097srt:EuropeMembercntg:DiagnosticsSegmentMember2020-07-012020-09-300001757097srt:EuropeMembercntg:Covid19Member2020-07-012020-09-300001757097srt:AsiaPacificMembercntg:DiagnosticsSegmentMember2020-07-012020-09-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMembercntg:PharmaceuticalSegmentMember2020-07-012020-09-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMembercntg:DiagnosticsSegmentMember2020-07-012020-09-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMembercntg:Covid19Member2020-07-012020-09-300001757097ifrs-full:PerformanceObligationsSatisfiedAtPointInTimeMembercntg:PharmaceuticalSegmentMember2020-07-012020-09-300001757097ifrs-full:PerformanceObligationsSatisfiedAtPointInTimeMembercntg:Covid19Member2020-07-012020-09-300001757097country:UScntg:PharmaceuticalSegmentMember2020-07-012020-09-300001757097country:UScntg:DiagnosticsSegmentMember2020-07-012020-09-300001757097country:UScntg:Covid19Member2020-07-012020-09-300001757097country:NLcntg:Covid19Member2020-07-012020-09-300001757097country:DEcntg:PharmaceuticalSegmentMember2020-07-012020-09-300001757097country:DEcntg:DiagnosticsSegmentMember2020-07-012020-09-300001757097country:DEcntg:Covid19Member2020-07-012020-09-300001757097cntg:IfrsMiddleEastMembercntg:PharmaceuticalSegmentMember2020-07-012020-09-300001757097cntg:IfrsMiddleEastMembercntg:DiagnosticsSegmentMember2020-07-012020-09-300001757097srt:NorthAmericaMember2020-07-012020-09-300001757097srt:LatinAmericaMember2020-07-012020-09-300001757097srt:EuropeMember2020-07-012020-09-300001757097srt:AsiaPacificMember2020-07-012020-09-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMember2020-07-012020-09-300001757097ifrs-full:PerformanceObligationsSatisfiedAtPointInTimeMember2020-07-012020-09-300001757097country:US2020-07-012020-09-300001757097country:NL2020-07-012020-09-300001757097country:DE2020-07-012020-09-300001757097cntg:PharmaceuticalSegmentMember2020-07-012020-09-300001757097cntg:IfrsMiddleEastMember2020-07-012020-09-300001757097cntg:DiagnosticsSegmentMember2020-07-012020-09-300001757097srt:NorthAmericaMembercntg:PharmaceuticalSegmentMember2020-01-012020-09-300001757097srt:NorthAmericaMembercntg:DiagnosticsSegmentMember2020-01-012020-09-300001757097srt:NorthAmericaMembercntg:Covid19Member2020-01-012020-09-300001757097srt:LatinAmericaMembercntg:DiagnosticsSegmentMember2020-01-012020-09-300001757097srt:LatinAmericaMembercntg:Covid19Member2020-01-012020-09-300001757097srt:EuropeMembercntg:PharmaceuticalSegmentMember2020-01-012020-09-300001757097srt:EuropeMembercntg:DiagnosticsSegmentMember2020-01-012020-09-300001757097srt:EuropeMembercntg:Covid19Member2020-01-012020-09-300001757097srt:AsiaPacificMembercntg:DiagnosticsSegmentMember2020-01-012020-09-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMembercntg:PharmaceuticalSegmentMember2020-01-012020-09-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMembercntg:DiagnosticsSegmentMember2020-01-012020-09-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMembercntg:Covid19Member2020-01-012020-09-300001757097ifrs-full:PerformanceObligationsSatisfiedAtPointInTimeMembercntg:PharmaceuticalSegmentMember2020-01-012020-09-300001757097ifrs-full:PerformanceObligationsSatisfiedAtPointInTimeMembercntg:Covid19Member2020-01-012020-09-300001757097country:UScntg:PharmaceuticalSegmentMember2020-01-012020-09-300001757097country:UScntg:DiagnosticsSegmentMember2020-01-012020-09-300001757097country:UScntg:Covid19Member2020-01-012020-09-300001757097country:NLcntg:DiagnosticsSegmentMember2020-01-012020-09-300001757097country:NLcntg:Covid19Member2020-01-012020-09-300001757097country:DEcntg:PharmaceuticalSegmentMember2020-01-012020-09-300001757097country:DEcntg:DiagnosticsSegmentMember2020-01-012020-09-300001757097country:DEcntg:Covid19Member2020-01-012020-09-300001757097cntg:IfrsMiddleEastMembercntg:PharmaceuticalSegmentMember2020-01-012020-09-300001757097cntg:IfrsMiddleEastMembercntg:DiagnosticsSegmentMember2020-01-012020-09-300001757097srt:NorthAmericaMember2020-01-012020-09-300001757097srt:LatinAmericaMember2020-01-012020-09-300001757097srt:EuropeMember2020-01-012020-09-300001757097srt:AsiaPacificMember2020-01-012020-09-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMember2020-01-012020-09-300001757097ifrs-full:PerformanceObligationsSatisfiedAtPointInTimeMember2020-01-012020-09-300001757097country:US2020-01-012020-09-300001757097country:NL2020-01-012020-09-300001757097country:DE2020-01-012020-09-300001757097cntg:PharmaceuticalSegmentMember2020-01-012020-09-300001757097cntg:IfrsMiddleEastMember2020-01-012020-09-300001757097cntg:DiagnosticsSegmentMember2020-01-012020-09-300001757097cntg:StateOfMecklenburgWesternPomeraniaMember2021-01-012021-09-300001757097country:US2021-09-300001757097cntg:Covid19Member2021-09-300001757097country:US2020-12-310001757097cntg:Covid19SegmentPartnerTwoMembercntg:Covid19Member2021-07-012021-09-300001757097cntg:Covid19SegmentPartnerOneMembercntg:Covid19Member2021-07-012021-09-300001757097cntg:Covid19SegmentPartnerTwoMembercntg:Covid19Member2021-01-012021-09-300001757097cntg:Covid19SegmentPartnerOneMembercntg:Covid19Member2021-01-012021-09-300001757097cntg:PharmaceuticalPartnerMembercntg:PharmaceuticalSegmentMember2020-07-012020-09-300001757097cntg:Covid19SegmentPartnerTwoMembercntg:Covid19Member2020-07-012020-09-300001757097cntg:Covid19SegmentPartnerOneMembercntg:Covid19Member2020-07-012020-09-300001757097cntg:PharmaceuticalPartnerMembercntg:PharmaceuticalSegmentMember2020-01-012020-09-300001757097cntg:Covid19SegmentPartnerTwoMembercntg:Covid19Member2020-01-012020-09-300001757097cntg:Covid19SegmentPartnerOneMembercntg:Covid19Member2020-01-012020-09-300001757097ifrs-full:OrdinarySharesMember2021-09-300001757097ifrs-full:OrdinarySharesMember2020-12-310001757097cntg:EquityShareOption2017EquitySettledMember2021-01-012021-09-300001757097cntg:StockOptionsMembercntg:LongTermIncentivePlanMember2020-12-310001757097cntg:EquityShareOption2017EquitySettledMember2020-12-310001757097cntg:IfrsRestrictedStockUnitsRsusMembercntg:LongTermIncentivePlanMember2020-12-310001757097cntg:IfrsRestrictedStockUnitsRsusMembercntg:SupervisoryBoardMembercntg:LongTermIncentivePlanMember2021-09-052021-09-050001757097cntg:IfrsRestrictedStockUnitsRsusMembercntg:LongTermIncentivePlanMember2021-01-012021-09-300001757097cntg:LpcGmbhMember2020-09-300001757097cntg:SupervisoryBoardMembercntg:LongTermIncentivePlanMember2021-09-052021-09-050001757097cntg:SupervisoryBoardMembersrt:MaximumMembercntg:LongTermIncentivePlanMember2021-07-312021-07-310001757097cntg:SupervisoryBoardMembercntg:LongTermIncentivePlanMember2021-07-312021-07-310001757097cntg:CostOfSaleMember2021-07-012021-09-300001757097cntg:CostOfSaleMember2021-01-012021-09-300001757097cntg:CostOfSaleMember2020-07-012020-09-300001757097cntg:CostOfSaleMember2020-01-012020-09-300001757097ifrs-full:IssuedCapitalMember2020-01-012020-09-300001757097ifrs-full:CapitalReserveMember2020-01-012020-09-300001757097cntg:FollowOnEquityOfferingMembercntg:SellingShareholdersMemberifrs-full:OrdinarySharesMemberifrs-full:MajorPurchasesOfAssetsMember2020-07-012020-07-310001757097cntg:FollowOnEquityOfferingMembercntg:CentogeneN.vMemberifrs-full:OrdinarySharesMemberifrs-full:MajorPurchasesOfAssetsMember2020-07-012020-07-310001757097cntg:SecuredBankLoanMember2021-09-300001757097cntg:SecuredBankLoanMember2020-12-310001757097cntg:OverdraftFacilityOneMember2020-12-310001757097ifrs-full:AnnouncingOrCommencingImplementationOfMajorRestructuringMember2021-10-012021-12-310001757097cntg:UnallocatedAmountsShareBasedPaymentsMember2021-07-012021-09-300001757097cntg:UnallocatedAmountsShareBasedPaymentsMember2021-01-012021-09-300001757097cntg:UnallocatedAmountsShareBasedPaymentsMember2020-07-012020-09-300001757097cntg:UnallocatedAmountsShareBasedPaymentsMember2020-01-012020-09-300001757097cntg:TradeReceivablesAndContractAssetsMemberifrs-full:NotLaterThanOneMonthMember2021-09-300001757097cntg:TradeReceivablesAndContractAssetsMemberifrs-full:LaterThanThreeMonthsMember2021-09-300001757097cntg:TradeReceivablesAndContractAssetsMemberifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember2021-09-300001757097cntg:TradeReceivablesAndContractAssetsMemberifrs-full:CurrentMember2021-09-300001757097cntg:TradeReceivablesAndContractAssetsMemberifrs-full:NotLaterThanOneMonthMember2020-12-310001757097cntg:TradeReceivablesAndContractAssetsMemberifrs-full:LaterThanThreeMonthsMember2020-12-310001757097cntg:TradeReceivablesAndContractAssetsMemberifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember2020-12-310001757097cntg:TradeReceivablesAndContractAssetsMemberifrs-full:CurrentMember2020-12-310001757097ifrs-full:RetainedEarningsMember2021-09-300001757097ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2021-09-300001757097ifrs-full:NoncontrollingInterestsMember2021-09-300001757097ifrs-full:IssuedCapitalMember2021-09-300001757097ifrs-full:EquityAttributableToOwnersOfParentMember2021-09-300001757097ifrs-full:CapitalReserveMember2021-09-300001757097ifrs-full:RetainedEarningsMember2020-12-310001757097ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2020-12-310001757097ifrs-full:NoncontrollingInterestsMember2020-12-310001757097ifrs-full:IssuedCapitalMember2020-12-310001757097ifrs-full:EquityAttributableToOwnersOfParentMember2020-12-310001757097ifrs-full:CapitalReserveMember2020-12-310001757097ifrs-full:RetainedEarningsMember2020-09-300001757097ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2020-09-300001757097ifrs-full:NoncontrollingInterestsMember2020-09-300001757097ifrs-full:IssuedCapitalMember2020-09-300001757097ifrs-full:EquityAttributableToOwnersOfParentMember2020-09-300001757097ifrs-full:CapitalReserveMember2020-09-300001757097ifrs-full:RetainedEarningsMember2019-12-310001757097ifrs-full:NoncontrollingInterestsMember2019-12-310001757097ifrs-full:IssuedCapitalMember2019-12-310001757097ifrs-full:EquityAttributableToOwnersOfParentMember2019-12-310001757097ifrs-full:CapitalReserveMember2019-12-310001757097cntg:ClosureOfHamburgLabMember2021-07-012021-09-300001757097cntg:ClosureOfHamburgLabMember2021-01-012021-09-300001757097cntg:ClosureOfHamburgLabMember2020-07-012020-09-300001757097cntg:ClosureOfHamburgLabMember2020-01-012020-09-300001757097cntg:UnallocatedAmountsDepreciationAndAmortizationMember2021-07-012021-09-300001757097cntg:UnallocatedAmountsDepreciationAndAmortizationMember2021-01-012021-09-300001757097cntg:UnallocatedAmountsDepreciationAndAmortizationMember2020-07-012020-09-300001757097cntg:UnallocatedAmountsDepreciationAndAmortizationMember2020-01-012020-09-300001757097ifrs-full:RetainedEarningsMember2021-01-012021-09-300001757097ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2021-01-012021-09-300001757097ifrs-full:NoncontrollingInterestsMember2021-01-012021-09-300001757097ifrs-full:IssuedCapitalMember2021-01-012021-09-300001757097ifrs-full:EquityAttributableToOwnersOfParentMember2021-01-012021-09-300001757097ifrs-full:CapitalReserveMember2021-01-012021-09-300001757097ifrs-full:RetainedEarningsMember2020-01-012020-09-300001757097ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2020-01-012020-09-300001757097ifrs-full:NoncontrollingInterestsMember2020-01-012020-09-300001757097ifrs-full:EquityAttributableToOwnersOfParentMember2020-01-012020-09-300001757097cntg:CentogeneN.v.CentogeneGmbhAndItsSubsidiariesMember2021-01-012021-09-3000017570972020-09-3000017570972019-12-310001757097ifrs-full:LeaseLiabilitiesMemberifrs-full:TopOfRangeMember2021-09-300001757097ifrs-full:LeaseLiabilitiesMemberifrs-full:BottomOfRangeMember2021-09-300001757097cntg:OtherBankLoansMember2021-09-300001757097cntg:TradeReceivablesAndContractAssetsMember2021-09-300001757097cntg:TradeReceivablesAndContractAssetsMember2020-12-310001757097cntg:Covid19Member2021-07-012021-09-300001757097cntg:Covid19Member2020-07-012020-09-300001757097cntg:Covid19Member2020-01-012020-09-300001757097cntg:LongTermIncentivePlanMember2021-07-012021-09-300001757097cntg:RostockHeadquartersBuildingMemberifrs-full:NotLaterThanOneYearMember2021-09-300001757097cntg:RostockHeadquartersBuildingMemberifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember2021-09-300001757097cntg:RostockHeadquartersBuildingMemberifrs-full:LaterThanFiveYearsMember2021-09-300001757097cntg:OfficeEquipmentAndStorageSpacesMemberifrs-full:NotLaterThanOneYearMember2021-09-300001757097cntg:OfficeEquipmentAndStorageSpacesMemberifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember2021-09-300001757097cntg:RostockHeadquartersBuildingMemberifrs-full:NotLaterThanOneYearMember2020-12-310001757097cntg:RostockHeadquartersBuildingMemberifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember2020-12-310001757097cntg:RostockHeadquartersBuildingMemberifrs-full:LaterThanFiveYearsMember2020-12-310001757097cntg:OfficeEquipmentAndStorageSpacesMemberifrs-full:NotLaterThanOneYearMember2020-12-310001757097cntg:OfficeEquipmentAndStorageSpacesMemberifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember2020-12-310001757097cntg:StockOptionsMembercntg:LongTermIncentivePlanMember2021-01-012021-09-300001757097cntg:StockOptionsMember2021-01-012021-09-300001757097cntg:FollowOnEquityOfferingMemberifrs-full:OrdinarySharesMemberifrs-full:MajorPurchasesOfAssetsMember2020-07-012020-07-310001757097cntg:OverdraftFacilityMember2021-09-300001757097cntg:OverdraftFacilityTwoMember2020-12-310001757097cntg:OverdraftFacilityMember2020-12-310001757097ifrs-full:OtherAssetsMemberifrs-full:OtherPropertyPlantAndEquipmentMember2021-09-300001757097ifrs-full:TopOfRangeMember2021-01-012021-09-300001757097ifrs-full:BottomOfRangeMember2021-01-012021-09-300001757097cntg:StockOptionsMembercntg:LongTermIncentivePlanMembercntg:VestingInThreeTranchesMember2021-09-300001757097cntg:StockOptionsMembercntg:LongTermIncentivePlanMember2021-09-300001757097cntg:EquityShareOption2017EquitySettledMember2021-09-300001757097cntg:IfrsRestrictedStockUnitsRsusMembercntg:LongTermIncentivePlanMember2021-09-3000017570972021-09-050001757097cntg:SupervisoryBoardMembercntg:LongTermIncentivePlanMember2021-07-310001757097cntg:PharmaceuticalPartnerMembercntg:PharmaceuticalSegmentMember2021-07-012021-09-300001757097cntg:Covid19SegmentPartnerMembercntg:Covid19Member2021-07-012021-09-300001757097cntg:PharmaceuticalPartnerMembercntg:PharmaceuticalSegmentMember2021-01-012021-09-300001757097cntg:Covid19SegmentPartnerMembercntg:Covid19Member2021-01-012021-09-300001757097cntg:Covid19Member2021-01-012021-09-300001757097cntg:RsuGrantedThreeMember2021-01-012021-09-300001757097cntg:LongTermIncentivePlanMember2021-01-012021-09-300001757097cntg:RsuGrantedTwoMember2021-01-012021-09-300001757097cntg:RsuGrantedOneMember2021-01-012021-09-300001757097cntg:RsuGrantedFourMember2021-01-012021-09-300001757097cntg:OptionsGrantedTwoMember2021-01-012021-09-300001757097cntg:OptionsGrantedOneMember2021-01-012021-09-300001757097cntg:OverdraftFacilityTwoMember2021-09-300001757097cntg:OverdraftFacilityOneMember2021-09-300001757097cntg:PartneringLaboratoryPhysicianProfDrPeterBauerMember2021-08-0700017570972020-01-012020-12-310001757097cntg:SecuredBankLoansWithMaturityPeriod2017To22Member2021-09-300001757097cntg:BankOverdraftsTwoMember2021-09-300001757097cntg:BankOverdraftsThreeMember2021-09-300001757097cntg:BankOverdraftsOneMember2021-09-300001757097cntg:SecuredBankLoansWithMaturityPeriod2017To22Member2020-12-310001757097cntg:BankOverdraftsTwoMember2020-12-310001757097cntg:BankOverdraftsThreeMember2020-12-310001757097cntg:BankOverdraftsOneMember2020-12-310001757097cntg:CentogeneN.v.CentogeneGmbhAndItsSubsidiariesMember2021-09-300001757097ifrs-full:AnnouncingOrCommencingImplementationOfMajorRestructuringMember2021-11-052021-11-050001757097cntg:UniversitairMedischCentrumUtrechtMember2021-09-300001757097cntg:StateOfMecklenburgWesternPomeraniaMember2021-09-300001757097cntg:UniversitairMedischCentrumUtrechtMember2018-11-080001757097ifrs-full:OtherAssetsMember2021-09-300001757097ifrs-full:OtherAssetsMember2020-12-310001757097ifrs-full:LeaseLiabilitiesMember2021-09-300001757097ifrs-full:BorrowingsByNameMember2021-09-300001757097cntg:SecuredCreditLinesMember2021-09-300001757097cntg:IfrsBankOverdraftsMember2021-09-3000017570972021-09-300001757097ifrs-full:LeaseLiabilitiesMember2020-12-310001757097ifrs-full:BorrowingsByNameMember2020-12-310001757097cntg:SecuredCreditLinesMember2020-12-310001757097cntg:OtherBankLoansMember2020-12-310001757097cntg:IfrsBankOverdraftsMember2020-12-3100017570972020-12-310001757097ifrs-full:OtherAssetsMembercntg:LpcGmbhMember2021-09-300001757097cntg:LpcGmbhMember2020-01-012020-09-300001757097ifrs-full:PropertyPlantAndEquipmentMembercountry:DEcntg:Covid19Member2021-07-012021-09-300001757097ifrs-full:PropertyPlantAndEquipmentMembercountry:DEcntg:Covid19Member2021-01-012021-09-300001757097ifrs-full:IntangibleAssetsOtherThanGoodwillMembercountry:DEcntg:Covid19Member2021-01-012021-09-300001757097ifrs-full:PropertyPlantAndEquipmentMembercountry:DEcntg:Covid19Member2020-07-012020-09-300001757097ifrs-full:IntangibleAssetsOtherThanGoodwillMembercountry:DEcntg:Covid19Member2020-07-012020-09-300001757097ifrs-full:PropertyPlantAndEquipmentMembercountry:DEcntg:Covid19Member2020-01-012020-09-300001757097ifrs-full:IntangibleAssetsOtherThanGoodwillMembercountry:DEcntg:Covid19Member2020-01-012020-09-300001757097ifrs-full:OtherAssetsMembercntg:RostockHeadquartersBuildingMember2021-09-300001757097ifrs-full:OtherAssetsMembercntg:BerlinOfficesMember2021-09-300001757097ifrs-full:OrdinarySharesMember2021-01-012021-09-300001757097ifrs-full:OrdinarySharesMember2020-01-012020-12-310001757097ifrs-full:OperatingSegmentsMember2021-07-012021-09-300001757097ifrs-full:OperatingSegmentsMember2021-01-012021-09-300001757097ifrs-full:OperatingSegmentsMember2020-07-012020-09-300001757097ifrs-full:OperatingSegmentsMember2020-01-012020-09-300001757097ifrs-full:OperatingSegmentsMembercntg:PharmaceuticalSegmentMember2021-07-012021-09-300001757097ifrs-full:OperatingSegmentsMembercntg:DiagnosticsSegmentMember2021-07-012021-09-300001757097ifrs-full:OperatingSegmentsMembercntg:Covid19Member2021-07-012021-09-300001757097cntg:IfrsCorporateMember2021-07-012021-09-3000017570972021-07-012021-09-300001757097ifrs-full:OperatingSegmentsMembercntg:PharmaceuticalSegmentMember2021-01-012021-09-300001757097ifrs-full:OperatingSegmentsMembercntg:DiagnosticsSegmentMember2021-01-012021-09-300001757097ifrs-full:OperatingSegmentsMembercntg:Covid19Member2021-01-012021-09-300001757097cntg:IfrsCorporateMember2021-01-012021-09-300001757097ifrs-full:OperatingSegmentsMembercntg:PharmaceuticalSegmentMember2020-07-012020-09-300001757097ifrs-full:OperatingSegmentsMembercntg:DiagnosticsSegmentMember2020-07-012020-09-300001757097ifrs-full:OperatingSegmentsMembercntg:Covid19Member2020-07-012020-09-300001757097cntg:IfrsCorporateMember2020-07-012020-09-3000017570972020-07-012020-09-300001757097ifrs-full:OperatingSegmentsMembercntg:PharmaceuticalSegmentMember2020-01-012020-09-300001757097ifrs-full:OperatingSegmentsMembercntg:DiagnosticsSegmentMember2020-01-012020-09-300001757097ifrs-full:OperatingSegmentsMembercntg:Covid19Member2020-01-012020-09-300001757097cntg:IfrsCorporateMember2020-01-012020-09-3000017570972020-01-012020-09-30iso4217:USDxbrli:sharesiso4217:CHFiso4217:EURxbrli:purecntg:claimcntg:customercntg:installmentxbrli:sharescntg:trancheiso4217:USDiso4217:EURxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the date of November 24, 2021

Commission File Number 001-39124

Centogene N.V.

(Translation of registrant’s name into English)

Am Strande 7

18055 Rostock

Germany

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F.... Form 40-F.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Centogene N.V.

On November 24, 2021, Centogene N.V. (the “Company”) issued a press release reporting its financial results for the nine months ended September 30, 2021. A copy of the press release is attached hereto as Exhibit 99.1.

Attached hereto as Exhibits 99.2, 99.3 and 99.4 are also the financial statements of the Company for the three and nine months ended September 30, 2021, the Management’s Discussion and Analysis of Financial Condition and Results of Operations for the three and nine months ended September 30, 2021, and a risk factor on Going Concern, respectively. All exhibits attached hereto are incorporated by reference herein.

Exhibit 99.1 to this Report on Form 6-K shall not be deemed “filed” for purposes of Section 18 of the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the U.S. Securities Act of 1933, as amended, or the Exchange Act.

Exhibits 99.2, 99.3 and 99.4 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statement on Form S-8 (Registration Number 333-234551) of the Company and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

2

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CENTOGENE N.V.

Date: November 24, 2021

By:

/s/ Rene Just

Name:

Rene Just

Title:

Chief Financial Officer

3

Exhibit Index

Exhibit

    

Description of Exhibit

                        

99.1

Press Release dated November 24, 2021

99.2

Unaudited Condensed Consolidated Interim Financial Statements as of and for the Three and Nine Months ended September 30, 2021

99.3

Management’s Discussion and Analysis of Financial Condition and Results of Operations for the Three and Nine Months ended September 30, 2021

99.4

Risk Factor on Going Concern

4

Exhibit 99.1

CENTOGENE Reports Third Quarter 2021 Financial Results

Second Consecutive Quarter of Core Business Growth, Phasing Out COVID-19 Testing and Restructuring Organization for Core Rare Disease Business


CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, November 24, 2021 (GLOBE NEWSWIRE– Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced financial results for the third quarter ended September 30, 2021, and provided a recent business update.

Executive Commentary

“We are encouraged by the progress achieved in Q3 on our continued path to return focus and growth to our rare disease business, driving strategic Core Business execution,” stated Andrin Oswald, M.D., Chief Executive Officer at CENTOGENE. “We saw continued recovery trends in the Diagnostics segment, with over 40% increase in revenues compared to Q3 2020. While recovery in Pharma revenues is lagging, we remain optimistic for acceleration in the fourth quarter, given the ongoing growth in signed contract value as our new management team gains traction with current and prospective Pharma partners.”

Q3 Financial Highlights

Overall revenues of 30.2 million in Q3 2021, a 17% decrease compared to €36.3 million in Q3 2020
Revenues from the Company’s Pharma and Diagnostics segments (“Core Business”) increased 13%, including Diagnostics revenues (excl. COVID) of €7.3 million, an increase of 43% compared to €5.1 million in Q3 2020, and Pharma revenues of €2.7 million in Q3 2021, a decrease of 28% compared to €3.8 million in Q3 2020
Commercial COVID-19 testing revenues of €20.2 million in Q3 2021, down from €27.4 million in Q3 2020
Total segment adjusted EBITDA of €(2.5) million compared to €9.2 million in Q3 2020 from the Company’s Pharma, Diagnostics, and COVID-19 testing segments, mainly reflecting the adjusted EBITDA contribution from COVID-19 testing having decreased by €13.4 million compared to the same quarter last year, partially offset by stronger adjusted EBITDA contribution from the Core Business segments
Cash and cash equivalents of €25.7 million as of September 30, 2021, compared to €34.8 million for the period ending June 30, 2021. There is uncertainty about the Company's ability to continue as a going concern. Please refer to the Company's Q3 2021 interim financial statements and related disclosures.

“While the business team’s full focus is on the Core Business, we are also prudently managing the phaseout of our ancillary COVID-19 testing business. We will leverage this process to also streamline the operational footprint for the Core Business and fully align with the strategic framework unveiled to the shareholders in June. This is expected to lead to savings of up to EUR 15 million annualized excluding restructuring costs, predominantly reflecting a reduction in personnel-related and operational expenditures and will reduce the Company’s cash burn rate,” added René Just, Chief Financial Officer of CENTOGENE.

Recent Business Highlights

Corporate

Added approximately 22,000 individuals to rare disease-centric Bio/Databank in Q3 2021. This is a one-of-a-kind real-world data repository which includes samples as well as data and cell lines for rare diseases from patients from over 120 countries
Published a research study in the New England Journal of Medicine highlighting ground-breaking family genetic research and path to a potential cure for structural birth defects. The study utilized insights gained from CENTOGENE’s Bio/Databank as part of a cross-organizational international team that analyzed data of more than 20,000 families. The findings provide a deeper understanding of syndromic structural birth defects and pave the way to advancing pharmacological treatment for the approximately 4 million infants every year that are born with these types of defects
Authored nine peer-reviewed scientific publications in Q3 2021, focused on generating critical insights into an array of diseases, including Parkinson’s disease, as well as structural birth defects


Pharma

Enrolled first patient in frontotemporal dementia (FTD) clinical study, which aims to enroll and complete data-rich genetic testing for more than 3,000 FTD patients at participating centers in Belgium, Germany, Greece, Italy, Portugal, Spain, and Turkey. The observational EFRONT Study is being conducted with support from Alector, Inc. Patients displaying the progranulin gene mutation (FTD-GRN) will have the option to enroll in Alector’s Phase 3 INFRONT-3 clinical trial
Expanded partnership with Agios Pharmaceuticals, Inc. to generate novel insights into rare blood diseases. CENTOGENE will provide genetic testing and clinical trial support via a three-year fee-for-service agreement for Agios’ three global, pivotal trials in thalassemia and sickle cell disease
Currently leading 12 observational longitudinal clinical studies to validate/monitor biomarkers, covering several disease categories, such as Parkinson’s disease, transthyretin amyloidosis, and inborn errors of metabolism

Diagnostic

Reported order intake of 14,770, which represents a 46% increase compared to 10,150 in the same period in 2020
Combined the Company’s expertise with Twist Bioscience to develop advanced sequencing tools to make genetic testing rapidly accessible for more patients with rare diseases

COVID-19 Testing & Organizational footprint

Leveraged CENTOGENE’s diagnostic expertise and resources with continued COVID-19 testing, including the processing of 342,300 test requests for SARS-CoV-2 testing in Q3 2021
Announced the phasing out of the non-core COVID-19 testing services by early 2022 and alignment of Company’s operational footprint with the strategic priorities on Core Business execution. As part of this restructuring, the Company will be eliminating approximately 80 positions in its Core Business employee base, which had a baseline of approximately 530 at the end of September 2021

2021 Financial Guidance

The Company updated its overall topline guidance and expects total revenue growth for FY2021 between 30-40% versus the prior year, driven mainly by COVID-19 related revenues. The portion of total revenues derived from COVID-19 testing has declined over the past three quarters and is expected to decline further in the fourth quarter – leading to a phaseout by the end of Q1 2022. After a decline of 20% from FY2019 to FY2020, the Company expects its Core Business to return to growth for FY2021 in the mid to high single digits.

Webcast and Conference Call Information

Management will host a conference call and webcast today at 2 p.m. CET/8 a.m. ET on November 24, 2021, to discuss financial results and recent developments. To access the conference call and webcast, please register at: http://emea.directeventreg.com/registration/6469305

Upon registering, each participant will be provided with Participant Dial-in information, a Direct Event Passcode, and a unique Registrant ID. Registrants can then join up to 10 minutes prior to the start of the call.

The webcast of the conference call and the slide deck will also be available on the Investor Relations page of the Company’s website at http://investors.centogene.com.

These results reflect another step forward for CENTOGENE’s mission to enable the cure of 100 rare diseases within the next 10 years. To learn more, visit: https://www.centogene.com/virtual-investor-event

About CENTOGENE

CENTOGENE engages in diagnosis and research around rare diseases transforming real-world clinical, genetic, and multiomic data to diagnose, understand, and treat rare diseases. Our goal is to bring rationality to treatment decisions and to accelerate the


development of new orphan drugs by using our extensive rare disease knowledge and data. CENTOGENE has developed a global proprietary rare disease platform based on our real-world data repository of over 600,000 patients representing over 120 different countries.

The Company’s platform includes epidemiologic, phenotypic, and genetic data that reflects a global population, as well as a biobank of patients’ blood samples and cell cultures. CENTOGENE believes this represents the only platform focused on comprehensive analysis of multi-level data to improve the understanding of rare hereditary diseases. It allows for better identification and stratification of patients and their underlying diseases to enable and accelerate discovery, development, and access to orphan drugs. As of December 31, 2020, the Company collaborated with over 30 pharmaceutical partners.

Follow us on LinkedIn 

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. federal securities laws. Statements contained herein that are not clearly historical in nature are forward-looking, and the words “anticipate,” “believe,” “continues,” “expect,” “estimate,” “intend,” “project,” and similar expressions and future or conditional verbs such as “will,” “would,” “should,” “could,” “might,” “can,” and “may,” are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause CENTOGENE’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, the effects of the COVID-19 pandemic on our business and results of operations, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in our industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, our reliance on third parties and collaboration partners, including our ability to manage growth and enter into new client relationships, our dependency on the rare disease industry, our ability to manage international expansion, our reliance on key personnel, our reliance on intellectual property protection, fluctuations of our operating results due to the effect of exchange rates, our ability to streamline cash usage, our requirement for additional financing and our ability to continue as a going concern, or other factors. For further information on the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to CENTOGENE’s business in general, see CENTOGENE’s risk factors set forth in CENTOGENE’s Form 20-F filed on April 15, 2021, with the Securities and Exchange Commission (the “SEC”) and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and CENTOGENE’s specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Media Contact:

CENTOGENE

Lennart Streibel 

Investor Relations 

Investor.Relations@centogene.com  

Ben Legg 

Corporate Communications 

Ben.Legg@centogene.com  

 
Stern IR  
Brendan Payne

+1 (212) 698 8695

brendan.payne@sternir.com


0.960.271.551.20P30DP20DP20D

Exhibit 99.2

Centogene N.V.

Unaudited interim condensed consolidated statements of comprehensive loss

for the three and nine months ended September 30, 2021, and 2020

(in EUR k)

    

    

For the three months ended September 30

    

For the nine months ended September 30

Note

2021

    

2020

    

2021

    

2020

Revenue

 

4, 5

30,196

36,305

 

147,027

58,129

Cost of sales

 

35,618

26,059

 

131,325

39,892

Gross (loss)/ profit

 

(5,422)

10,246

 

15,702

18,237

Research and development expenses

 

3,821

4,796

 

12,209

10,606

General administrative expenses

 

10,406

8,373

 

32,496

24,038

Selling expenses

 

2,206

1,300

 

6,097

6,012

Impairment of financial assets

 

7

502

1,147

 

1,177

2,821

Other operating income

 

6.1

1,011

679

 

2,653

2,425

Other operating expenses

 

6.2

53

 

36

191

Operating loss

 

  

(21,346)

(4,744)

 

(33,660)

(23,006)

Interest and similar income

 

  

 

6

Interest and similar expense

 

  

263

793

 

734

1,504

Financial costs, net

 

(263)

(793)

 

(734)

(1,498)

Loss before taxes

 

  

(21,609)

(5,537)

 

(34,394)

(24,504)

Income tax expenses

 

35

103

 

159

232

Loss for the period

 

  

(21,644)

(5,640)

 

(34,553)

(24,736)

Other comprehensive income/ (loss), all attributable to equity holders of the parent

 

  

86

(66)

 

16

4

Total comprehensive loss

 

  

(21,558)

(5,706)

 

(34,537)

(24,732)

Attributable to:

 

  

 

Equity holders of the parent

 

  

(21,610)

(5,708)

 

(34,635)

(24,671)

Non‑controlling interests

 

  

52

2

 

98

(61)

(21,558)

(5,706)

 

(34,537)

(24,732)

Loss per share - Basic and diluted (in EUR)

 

  

(0.96)

(0.27)

 

(1.55)

(1.20)

The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements

1

Centogene N.V.

Unaudited interim condensed consolidated statements of financial position

as at September 30, 2021, and December 31, 2020

(in EUR k)

Assets

    

Note

    

Sep 30, 2021

Dec 31, 2020

Noncurrent assets

 

  

 

  

 

  

Intangible assets

 

 

11,407

12,407

Property, plant and equipment

 

 

12,160

16,590

Right-of-use assets

19,241

22,120

Other assets

 

7

 

2,973

1,967

 

45,781

53,084

Current assets

 

  

 

Inventories

 

 

4,922

11,405

Trade receivables and contract assets

 

7

 

13,907

29,199

Other assets

 

7

 

5,848

8,286

Cash and cash equivalents

 

8

 

25,732

48,156

 

50,409

97,046

 

96,190

150,130

Equity and liabilities

    

Note

    

Sep 30, 2021

Dec 31, 2020

Equity

 

  

 

  

 

  

Issued capital

 

9

 

2,701

2,654

Capital reserve

 

9

 

132,005

125,916

Retained earnings and other reserves

 

  

 

(97,523)

(62,888)

Non‑controlling interests

 

  

 

193

95

 

37,376

65,777

Noncurrent liabilities

 

  

 

Non‑current loans

 

10.1

 

100

401

Lease liabilities

 

10.1

 

15,560

17,677

Deferred tax liabilities

 

 

248

207

Government grants

 

10.2

 

8,228

8,950

 

24,136

27,235

Current liabilities

 

  

 

Government grants

 

10.2

 

1,375

1,342

Current loans

 

10.1

 

3,842

2,492

Lease liabilities

 

10.1

 

3,221

3,528

Trade payables

 

10.2

 

8,810

31,736

Liabilities from income taxes

10.2

177

58

Other liabilities

 

10.2

 

17,253

17,962

 

34,678

57,118

 

96,190

150,130

The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements

2

Centogene N.V.

Unaudited interim condensed consolidated statements of cash flows

for the nine months ended September 30, 2021, and 2020

(in EUR k)

For the nine months ended September 30

    

Note

    

2021

2020

Operating activities

 

  

 

  

  

Loss before taxes

 

  

 

(34,394)

(24,504)

Adjustments to reconcile loss to cash flow from operating activities

 

  

 

Depreciation and amortization

 

5

 

13,476

6,943

Inventory write-off

1,795

Interest income

 

 

(6)

Interest expense

 

 

734

1,504

Loss on the disposal of property, plant and equipment

352

Expected credit loss allowances on trade receivables and contract assets

7

1,177

2,821

Share‑based payment expenses

 

11

 

6,136

2,542

Tax expense

160

Other non‑cash items

 

  

 

(300)

(1,800)

Changes in operating assets and liabilities

 

  

 

Inventories

 

 

4,688

(5,482)

Trade receivables and contract assets

 

7

 

14,115

(12,015)

Other assets

 

7

 

594

5,605

Trade payables

 

10.2

 

(22,926)

3,498

Other liabilities

 

10.2

 

(590)

1,225

Cash flow used in operating activities

 

  

 

(14,983)

(19,669)

Investing activities

 

  

 

Cash paid for investments in intangible assets

 

5

 

(2,567)

(4,781)

Cash paid for investments in property, plant and equipment

 

5

 

(2,829)

(6,641)

Grants received for investment in property, plant and equipment

 

10.2

 

390

Interest received

6

Cash flow used in investing activities

 

  

 

(5,396)

(11,026)

Financing activities

 

  

 

Cash received from issuance of shares

22,430

Cash paid for acquisition of non-wholly owned subsidiary

(75)

Cash received from loans

 

10.1

 

1,910

1,114

Cash repayments of loans

 

10.1

 

(467)

(1,260)

Cash repayments of lease liabilities

 

10.1

 

(3,301)

(2,833)

Interest paid

 

 

(187)

(1,028)

Cash flow used in/ generated from financing activities

 

  

 

(2,045)

18,348

Changes in cash and cash equivalents

 

  

 

(22,424)

(12,347)

Cash and cash equivalents at the beginning of the period

 

  

 

48,156

41,095

Cash and cash equivalents at the end of the period

 

  

 

25,732

28,748

The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements

3

Centogene N.V.

Unaudited interim condensed consolidated statements of changes in equity

for the nine months ended September 30, 2020, and 2021

Attributable to the owners of the parent

Currency

Non-

Issued

Capital

translation

Retained

controlling

Total

in EUR k

    

Note

    

capital

    

reserve

    

reserve

    

earnings

    

Total

    

interests

    

equity

 

As of January 1, 2020

2,383

98,099

(40,622)

59,860

(938)

58,922

Loss for the period

  

(24,675)

(24,675)

(61)

(24,736)

Other comprehensive loss

  

4

4

4

Total comprehensive loss

 

 

4

 

(24,675)

 

(24,671)

 

(61)

 

(24,732)

Share-based payments

11

2,542

2,542

2,542

Issuance of shares

240

22,969

23,209

23,209

Exercise of options

30

(30)

Transaction costs

(779)

(779)

(779)

Disposal of non-wholly owned subsidiary

6.2

268

268

Acquisition of non-wholly owned subsidiary

(780)

(780)

705

(75)

As of September 30, 2020

2,623

 

122,831

 

4

 

(66,077)

 

59,381

 

(26)

 

59,355

Attributable to the owners of the parent

Currency

Non-

Issued

Capital

translation

Retained

controlling

Total

in EUR k

    

Note

    

capital

    

reserve

    

reserve

    

earnings

    

Total

    

interests

    

equity

 

As of January 1, 2021

2,654

125,916

(48)

(62,840)

65,682

95

65,777

Loss for the period

  

(34,651)

(34,651)

98

(34,553)

Other comprehensive loss

  

16

16

16

Total comprehensive loss

 

 

16

 

(34,651)

 

(34,635)

 

98

 

(34,537)

Share-based payments

11

6,136

6,136

6,136

Exercise of options

47

(47)

As of September 30, 2021

2,701

 

132,005

 

(32)

 

(97,491)

 

37,183

 

193

 

37,376

The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements

4

Notes to the unaudited interim condensed consolidated financial statements as of September 30, 2021 and December 31, 2020 and for the three months and nine months ended September 30, 2021, and 2020

1General Company Information

Centogene N.V. (“the Company”) and its subsidiaries (“the Group”) focus on rare diseases and seek to transform real-world clinical and genetic or other data into actionable information for patients, physicians and pharmaceutical companies. The mission of the Company is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using our knowledge of the global rare disease market, including epidemiological and clinical data and innovative biomarkers.

On November 7, 2019, the Company completed an initial public offering (“IPO”) and has since been listed on Nasdaq Global Market under stock code “CNTG”. Centogene N.V. is a public company with limited liability incorporated in the Netherlands, with registered office located at Am Strande 7 in 18055 Rostock, Germany and Dutch trade register number 72822872.

In July 2020, the Company completed a follow-on offering of 3,500,000 common shares of the Company (the “Follow-on Equity Offering”), consisting of 2,000,000 common shares offered by the Company and 1,500,000 common shares offered by selling shareholders at a price to the public of US$ 14.00 per common share (i.e. EUR 12.71 per share). Aggregate offering proceeds, net of underwriting discounts, commissions and transaction costs, were EUR 22 million to the Company.

2Basis of Preparation

The interim condensed consolidated financial statements for the three and nine months ended September 30, 2020 and 2021 have been prepared in accordance with IAS 34 Interim Financial Reporting.

The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group’s annual consolidated financial statements as of December 31, 2019, and 2020 and for the three years ended December 31, 2020. Unless otherwise specified, "the Company" refers to Centogene N.V. and Centogene GmbH throughout the remainder of these notes, while "the Group" refers to Centogene N.V., Centogene GmbH and its subsidiaries.

The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group’s annual consolidated financial statements for the year ended December 31, 2020, except as described below. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective, and there are no new or amended standards or interpretations that are issued and became effective for the 2021 annual reporting period, that have a material impact on the Group.

These interim condensed consolidated financial statements are presented in euro, which is the Group's functional currency. Unless otherwise specified, all financial information presented in euro is rounded to the nearest thousand (EUR k) in line with customary commercial practice.

2.1New significant accounting policies and accounting judgments and estimates

Revenues from contracts with customer

The Group has a diagnostics customer from the Middle Eastern region with a history of significant payment delays. This history has resulted in the recognition of significant subsequent impairment losses by applying the expected credit loss method as the collection of the contractual consideration was historically considered probable upon recognition of revenue. Based on recent developments in its collection experience, recent negotiations with the customer, and past experiences, the Group considered it necessary to reassess its judgments related to the recognition of revenue from contracts with this customer.

The Group’s management concluded, based on the facts and circumstances and management’s expectations regarding this customer, that this uncertainty in the amount of the contract consideration it expects to collect, and the

5

Notes to the unaudited interim condensed consolidated financial statements as of September 30, 2021 and December 31, 2020 and for the three months and nine months ended September 30, 2021, and 2020

likelihood of accepting a lower amount or changing payment terms represents an “implicit price concession” such that the contract consideration is variable. Therefore, the Group’s management estimates the amount of the contractual consideration it expects to ultimately collect and for which it is highly probable that related revenue recognized would not be subject to significant future reversals when such uncertainty is resolved. The Group’s management estimates the implicit price concessions by applying an estimated rate of 18% based primarily upon past collection history.

Despite the uncertainties related to the amount expected to be collected from the customer, based on experience and the facts and circumstances related to the customer, the Group considers it probable that it will collect 82% of the amount of estimated variable transaction price due to newly agreed payment plans established with the customer. Therefore, the Group records the difference between the billed amount and the amount estimated to be collectible as a reduction to revenue. At the end of each reporting period, and if necessary upon receipt of new information, the Group may revise the amount of the variable consideration included in the transaction price. The Group has applied this accounting policy and accounting estimate to arrangements with this customer prospectively with effect to during the third quarter of 2021.

2.2Going Concern

As an early commercial-stage company, the Group is still in progress towards reaching break-even in its diagnostic and pharma businesses. The Group and Company are subject to a number of risks similar to those of other development and early commercial stage companies. These risks include, among other things, the failure to enter into and successfully execute further collaborations with pharmaceutical partners, the failure to generate revenue from the Company’s development portfolio and risks associated with research, development, testing and obtaining related regulatory approvals in relation to our product candidates. The Group´s ongoing success and ultimately the attainment of profitable operations depends on future uncertain events which include, among other things, obtaining adequate financing to promote our commercial and development activities until the Group can generate sufficient revenues to support its operating cash requirements.

The Group has incurred operating losses since inception. For the nine months ended September 30, 2021 the Group incurred a net loss of € 34.6 million of which € 33.7 million are related to loss of operations, resulting in an operating cash outflow of € 15.0 million). As of September 30, 2021, the Group had generated an accumulated deficit of € 97.5 million, and had an equity position of € 37.4 million.

Considering cash and cash equivalents as of September 30, 2021 of € 25.7 million with relatively low short term debt obligations of € 4.0 million and no financial covenants, the Group has prepared cash flow forecasts and considered the cash flow requirement for the Company, principally focused on the twelve month period from the date of the approval of the unaudited interim condensed consolidated financial statements. These forecasts show that further financings will be required during the course of the next 12 months assuming, among others, that development programs and other operating activities continue as currently planned including the implementation of certain planned cost saving measures. This requirement for additional financing represents a material uncertainty that raises significant doubt about our ability to continue as a going concern. Without such funding considered, the Group’s current cash and cash equivalents will not be sufficient to fund its operations and meet all of its obligations as they fall due for at least one year from the date of the issuance of these unaudited interim condensed consolidated financial statements.

Consequently, until the Group completes a significant financing, it plans to obtain interim bridge financing, enact measures aimed at reducing personnel and infrastructure costs, and where possible, operate at a lower spending level by pacing investments on new research programs. Additionally, the Group plans to seek funds through further private or public equity financings, debt financings, strategic collaborations and marketing, distribution or licensing arrangements, business and asset divestitures and grant funding among other things. Despite the Company’s efforts to obtain the necessary funding and improve profitability of its operations, there can be no assurance of its success in doing so, or obtaining necessary funding on acceptable terms.

6

Notes to the unaudited interim condensed consolidated financial statements as of September 30, 2021 and December 31, 2020 and for the three months and nine months ended September 30, 2021, and 2020

The accompanying unaudited interim condensed consolidated financial statements for the three and nine months ended September 30, 2021 have been therefore prepared on a going concern basis contingent upon the successful implementation of the plans described above. This contemplates the Group will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of operations. The unaudited interim condensed consolidated financial statements do not reflect any adjustments relating to the recoverability and classification of assets or the amounts and classification of liabilities that would be necessary, was the Group unable to continue as a going concern.

3Effect of COVID-19 Pandemic

The COVID-19 pandemic has spread worldwide and continues to cause many governments to maintain measures to slow the spread of the outbreak through quarantines, travel restrictions, closures of borders and requiring maintenance of physical distance between individuals.

Since the second quarter of 2020, the COVID-19 pandemic has resulted in a slowdown in our diagnostics and pharmaceutical businesses. As part of the Company’s initiative to assist local, national and international authorities as well as other partners in their efforts to facilitate the earliest possible diagnosis of COVID-19 and thereby contribute to allowing society to return to a “new” normal, the Company commenced testing for COVID-19 in March 2020.

During the nine months ended September 30, 2021, the Group continued the COVID-19 testing activities started in 2020 with a leading role in providing testing services at airports in Germany. Furthermore, new variants of the virus have emerged since mid-December 2020. How these mutations develop and their impact on the effectiveness of vaccines is not yet fully clear. Furthermore, vaccination campaigns in several countries started during the nine months ended September 30, 2021, and due to the expected increase in the availability of vaccines until the end of the year, the expectation is that governments will reduce restrictions during 2021. As a result of these developments in the COVID-19 pandemic, the Group has noticed a decrease in COVID-19 test order intakes in the three months ended September 30, 2021. How and when these developments would affect the potential prolongation of the need for testing on a broader scale remains uncertain.

Although the Group is taking a number of measures aimed at minimizing disruptions to the business and operations, and while the provision of testing for the COVID-19 virus is anticipated to generate additional revenues for us, the full extent to which the global COVID-19 pandemic may impact the business will depend on future developments, which are highly uncertain and cannot be predicted, such as the duration of the pandemic, the availability and effectiveness of vaccines against new variants, the probability of the occurrence of further outbreaks and the ultimate impact on the financial markets and the global economy, and could result in an unforeseen negative impact on the business and future results of operations.

7

Notes to the unaudited interim condensed consolidated financial statements as of September 30, 2021 and December 31, 2020 and for the three months and nine months ended September 30, 2021, and 2020

4Revenues from Contracts with Customers

in EUR k

Three Months Ended September 30, 2021

    

Pharmaceutical

    

Diagnostics

COVID-19

    

Total

Rendering of services

2,532

7,261

20,203

29,996

Sales of goods

200

200

Total Revenues from contracts with external customers

2,732

7,261

20,203

30,196

Recognized over time

2,532

7,261

109

9,902

Recognized at a point in time

200

20,094

20,294

Total Revenues from contracts with external customers

2,732

7,261

20,203

30,196

    

Geographical information

 

Europe

 

2

1,479

19,971

21,452

—Germany*#

 

48

19,913

19,961

—Netherlands**

1

64

65

Middle East

 

18

4,033

4,051

North America

 

2,696

908

232

3,836

—United States#

2,696

867

232

3,795

Latin America

 

16

661

677

Asia Pacific

 

180

180

Total Revenues from contracts with external customers

 

2,732

 

7,261

20,203

 

30,196

*Country of the incorporation of Centogene GmbH

**Country of the incorporation of Centogene N.V.

#

Countries contributing more than 10% of the Group’s total consolidated revenues for the three months ended September 30, 2020, and 2021, respectively.

in EUR k

Three Months Ended September 30, 2020

    

Pharmaceutical

    

Diagnostics

    

COVID-19

Total

Rendering of services

3,598

5,069

26,795

35,462

Sales of goods

202

641

843

Total Revenues from contracts with external customers

3,800

5,069

27,436

36,305

Recognized over time

3,598

5,069

8,693

17,360

Recognized at a point in time

202

18,743

18,945

Total Revenues from contracts with external customers

3,800

5,069

27,436

36,305

Geographical information

Europe

 

39

1,547

 

27,238

28,824

—Germany*#

 

20

52

 

26,568

26,640

—Netherlands**

 

2

2

Middle East

 

26

2,648

 

2,674

North America

 

3,735

333

 

197

4,265

—United States#

 

3,735

299

 

197

4,231

Latin America

 

398

 

1

399

Asia Pacific

 

143

 

143

Total Revenues from contracts with external customers

 

3,800

 

5,069

 

27,436

36,305

8

Notes to the unaudited interim condensed consolidated financial statements as of September 30, 2021 and December 31, 2020 and for the three months and nine months ended September 30, 2021, and 2020

in EUR k

Nine months ended September 30, 2021

    

Pharmaceutical

    

Diagnostics

COVID-19

Total

Rendering of services

8,578

20,359

117,505

146,442

Sales of goods

583

2

585

Total Revenues from contracts with external customers

9,161

20,359

117,507

147,027

Recognized over time

8,578

20,359

19,081

48,018

Recognized at a point in time

583

98,426

99,009

Total Revenues from contracts with external customers

9,161

20,359

117,507

147,027

    

Geographical information

 

Europe

 

200

4,013

116,253

120,466

—Germany*#

 

158

112,581

112,739

Netherlands**

6

3,603

3,609

Middle East

 

73

12,118

12,191

North America

 

8,832

2,062

1,176

12,070

Latin America

 

56

1,679

1,735

Asia Pacific

 

487

78

565

Total Revenues from contracts with external customers

 

9,161

20,359

117,507

147,027

*Country of the incorporation of Centogene GmbH

**Country of the incorporation of Centogene N.V.

#

Countries contributing more than 10% of the Group’s total consolidated revenues for the nine months ended September 30, 2020, and 2021, respectively.

in EUR k

Nine months ended September 30, 2020

    

Pharmaceutical

    

Diagnostics

    

COVID-19

Total

Rendering of services

11,478

16,308

28,848

56,634

Sales of goods

812

683

1,495

Total Revenues from contracts with external customers

12,290

16,308

29,531

58,129

Recognized over time

11,478

16,308

9,215

37,001

Recognized at a point in time

812

20,316

21,128

Total Revenues from contracts with external customers

12,290

16,308

29,531

58,129

    

Geographical information

 

Europe

 

106

4,282

29,323

33,711

—Germany*#

 

58

144

28,645

28,847

Netherlands**